PMID

Data

Article Title

Citation

Organization

Deposition

Files Download

 

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

bioRxiv 2022: (2022)

Shionogi Pharmaceutical Research Center

02/02/22

2D 3D

Perspectives on SARS-CoV-2 Main Protease Inhibitors.

J Med Chem 64: 16922-16955 (2021)

Michigan State University

01/27/22

2D 3D

Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections

WIPO WO2021219089A1 (2021)

Insilico Medicine Ip Limited

01/27/22

2D 3D

Compounds and method of treating covid-19

WIPO WO2021205290A1 (2021)

Pfizer Inc.

01/13/22

2D 3D

Inhibitors of cysteine proteases and methods of use thereof

US Patent US11124497 (2021)

Pardes Biosciences, Inc.

01/13/22

2D 3D

Nitrile-containing antiviral compounds

WIPO WO2021250648A1 (2021)

Pfizer Inc.

01/13/22

2D 3D

Compounds and methods for the treatment of covid-19

WIPO WO2021205298A1 (2021)

Pfizer Inc.

01/13/22

2D 3D

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.

J Am Chem Soc 143: 20697-20709 (2021)

The University of Arizona

01/13/22

2D 3D

Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.

J Med Chem (2021)

University of Illinois at Chicago

11/05/21

2D 3D

Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.

J Med Chem 64: 14702-14714 (2021)

Purdue University

11/05/21

2D 3D

A patent review on SARS coronavirus main protease (3CLpro) inhibitors.

ChemMedChem (2021)

Experimental Drug Development Centre

11/05/21

2D 3D

 

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Science 374: 1-13 (2021)

Pfizer

11/05/21

2D 3D

 

Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics

bioRxiv 2021: (2021)

Israel Institution of Biological Research

11/05/21

2D 3D

DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 M

Proc Natl Acad Sci U S A 118: (2021)

Baylor College of Medicine

09/11/21

2D 3D

Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.

ACS Med Chem Lett 12: 1325-1332 (2021)

Yale University

09/10/21

2D 3D

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.

ACS Pharmacol Transl Sci 4: 1408-1421 (2021)

The University of Arizona

09/10/21

2D 3D

Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL

J Med Chem 64: (2021)

Cleveland Clinic

08/14/21

2D 3D

Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease.

J Med Chem 64: 10047-10058 (2021)

Wichita State University

07/29/21

2D 3D

A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.

Bioorg Med Chem Lett 48: 128263 (2021)

A*STAR

07/29/21

2D 3D

Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency

ACS Med Chem Lett 12: 1325-1332 (2021)

Yale University

07/29/21

2D 3D

Peptidomimetic ?-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and

J Med Chem (2021)

University of Alberta

07/29/21

2D 3D

Highly active compounds against COVID-19

US Patent US10874687 (2020)

Atea Pharmaceuticals, Inc.

07/25/21

2D 3D

SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

Science (2021)

Sichuan University

02/28/21

2D 3D

 

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

ACS Cent Sci (2021)

Yale University

02/28/21

2D 3D

Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling.

Bioorg Med Chem 27: 1981-1989 (2019)

University of Illinois at Chicago

02/24/21

2D 3D

 

Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen

bioRxiv 2020: (2020)

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) and Fraunhofer Cluster of Excellence for Immune mediated diseases (CIMD)

01/31/21

2D 3D

Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis

WIPO WO2006061714A2 (2006)

Pfizer Inc.

01/31/21

2D 3D

 

Inhibition of SARS-CoV-2 main protease by allosteric drug-binding

bioRxiv 2020: (2020)

Center for Free-Electron Laser Science

01/31/21

2D 3D

A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

ChemMedChem (2020)

Texas A&M University

01/31/21

2D 3D

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.

Sci Transl Med 12: 1-15 (2020)

University of North Carolina at Chapel Hill

11/13/20

2D 3D

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.

Antimicrob Agents Chemother 64: (2020)

Institut Pasteur Korea

11/13/20

2D 3D

The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.

Med Res Rev (2020)

University of Bonn

11/07/20

2D 3D

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.

J Med Chem 59: 6595-628 (2016)

University of Bonn

11/07/20

2D 3D

Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis

WIPO WO2005113580A1 (2005)

Pfizer Inc.

10/17/20

2D 3D

Broad-spectrum non-covalent coronavirus protease inhibitors

US Patent US9975885 (2018)

PURDUE RESEARCH FOUNDATION

09/25/20

2D 3D

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.

bioRxiv (2020)

National Institutes of Health

09/21/20

2D 3D

 

Discovery of potent inhibitors of PLproCoV2 by screening a library of selenium-containing compounds

bioRxiv 1-12 (2020)

University ofAmsterdam

09/21/20

2D 3D

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors.

Science 368: 409-412 (2020)

University of Lubeck

09/21/20

2D 3D

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.

Science 368: 1331-1335 (2020)

Shanghai Institute of Materia Medica

09/21/20

2D 3D

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19.

bioRxiv (2020)

Pfizer Inc.

09/21/20

2D 3D

Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.

ACS Infect Dis 6: 2099-2109 (2020)

University of Georgia

09/21/20

2D 3D

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.

Biochem Biophys Res Commun 333: 194-9 (2005)

National Taiwan University

09/21/20

2D 3D

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Nature 582: 289-293 (2020)

ShanghaiTech University

09/06/20

2D 3D

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.

Sci Transl Med 12: (2020)

Wichita State University

09/06/20

2D 3D

Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.

Bioorg Med Chem 22: 292-302 (2014)

Tianjin University of Science and Technology

09/02/20

2D 3D

Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings.

Bioorg Med Chem 22: 167-77 (2014)

University of Illinois at Chicago

09/02/20

2D 3D

Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.

Bioorg Med Chem Lett 23: 6317-20 (2013)

Kansas State University

09/01/20

2D 3D

Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases.

Eur J Med Chem 59: 1-6 (2013)

The Chinese University of Hong Kong

08/31/20

2D 3D

Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.

Bioorg Med Chem 18: 7849-54 (2010)

Academia Sinica

08/28/20

2D 3D

Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.

Bioorg Med Chem 17: 5139-45 (2009)

National Human Genome Research Institute

08/27/20

2D 3D

SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.

Bioorg Med Chem Lett 20: 1873-6 (2010)

Korea Research Institute of Bioscience and Biotechnology

08/27/20

2D 3D

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.

Bioorg Med Chem Lett 19: 2722-7 (2009)

Kyoto Pharmaceutical University

08/27/20

2D 3D

Novel small-molecule inhibitors of transmissible gastroenteritis virus.

Antimicrob Agents Chemother 51: 3924-31 (2007)

National Health Research Institute

08/27/20

2D 3D

Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.

Bioorg Med Chem Lett 17: 5876-80 (2007)

Purdue University

08/24/20

2D 3D

Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.

Eur J Med Chem 150: 334-346 (2018)

Wichita State University

08/16/20

2D 3D

Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.

Bioorg Med Chem 24: 3035-3042 (2016)

Academia Sinica

09/14/17

2D 3D

Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.

J Enzyme Inhib Med Chem 29: 59-63 (2014)

Gyeongsang National University

08/28/17

2D 3D

Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.

ACS Chem Biol 10: 1456-65 (2015)

University of Illinois at Chicago

10/15/15

2D 3D

Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.

Bioorg Med Chem 20: 5928-35 (2012)

Korea Research Institute of Bioscience and Biotechnology

05/17/13

2D 3D

Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.

J Biol Chem 284: 7646-55 (2009)

National Yang-Ming University

10/29/12

2D 3D

Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.

Bioorg Med Chem Lett 21: 3088-91 (2011)

Chonnam National University

12/04/11

2D 3D

Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.

Chem Biol 13: 261-8 (2006)

Academia Sinica

07/07/11

2D 3D

Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives.

Bioorg Med Chem Lett 19: 4538-41 (2009)

Konkuk University

08/27/10

2D 3D

Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase.

Bioorg Med Chem Lett 19: 1636-8 (2009)

Konkuk University

01/11/10

2D 3D

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors.

J Med Chem 48: 6767-71 (2005)

Purdue University

11/10/09

2D 3D

Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.

J Med Chem 50: 1850-64 (2007)

University of Alberta

11/10/09

2D 3D

Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.

J Med Chem 49: 3440-3 (2006)

Peking University

11/10/09

2D 3D

Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.

Bioorg Med Chem Lett 15: 3058-62 (2005)

Development Center for Biotechnology

11/10/09

2D 3D

Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease.

J Med Chem 52: 5228-40 (2009)

Purdue University

09/14/09

2D 3D

Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.

Bioorg Med Chem 16: 4138-49 (2008)

University of Mississippi

07/08/08

2D 3D

Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.

J Med Chem 49: 3485-95 (2006)

National Tsing Hua University

09/26/06

2D 3D

Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.

Bioorg Med Chem 13: 5240-52 (2005)

National Taiwan University

09/26/06

2D 3D

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.

J Med Chem 49: 5154-61 (2006)

National Defense Medical Center

09/26/06

2D 3D

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.

J Med Chem 48: 4469-73 (2005)

National Taiwan University

09/26/06

2D 3D

Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.

J Med Chem 49: 4971-80 (2006)

TaiGen Biotechnology Co.

09/23/06

2D 3D